DK0960886T3 - Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose - Google Patents
Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel skleroseInfo
- Publication number
- DK0960886T3 DK0960886T3 DK99101349T DK99101349T DK0960886T3 DK 0960886 T3 DK0960886 T3 DK 0960886T3 DK 99101349 T DK99101349 T DK 99101349T DK 99101349 T DK99101349 T DK 99101349T DK 0960886 T3 DK0960886 T3 DK 0960886T3
- Authority
- DK
- Denmark
- Prior art keywords
- absent
- thr
- ser
- gly
- cys
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 108010071384 Peptide T Proteins 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 abstract 1
- 206010028570 Myelopathy Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000029033 Spinal Cord disease Diseases 0.000 abstract 1
- 206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005934 immune activation Effects 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85883292A | 1992-03-27 | 1992-03-27 | |
| DK92645A DK64592D0 (da) | 1992-05-14 | 1992-05-14 | Peptider til terapeutisk behandling |
| US91511892A | 1992-07-17 | 1992-07-17 | |
| US98767492A | 1992-12-09 | 1992-12-09 | |
| EP99101349A EP0960886B1 (en) | 1992-03-27 | 1993-03-29 | Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis |
| EP93907942A EP0635027B1 (en) | 1992-03-27 | 1993-03-29 | Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0960886T3 true DK0960886T3 (da) | 2004-09-27 |
Family
ID=27439352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99101349T DK0960886T3 (da) | 1992-03-27 | 1993-03-29 | Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose |
| DK93907942T DK0635027T3 (da) | 1992-03-27 | 1993-03-29 | Peptid T og beslægtede peptider til behandling af inflammation, herunder dissemineret sclerose |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93907942T DK0635027T3 (da) | 1992-03-27 | 1993-03-29 | Peptid T og beslægtede peptider til behandling af inflammation, herunder dissemineret sclerose |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP0960886B1 (da) |
| JP (1) | JP3520084B2 (da) |
| KR (1) | KR100312300B1 (da) |
| AT (2) | ATE267838T1 (da) |
| AU (3) | AU684713B2 (da) |
| CA (1) | CA2132516A1 (da) |
| DE (2) | DE69333537T2 (da) |
| DK (2) | DK0960886T3 (da) |
| ES (2) | ES2222625T3 (da) |
| PT (1) | PT960886E (da) |
| UA (1) | UA41881C2 (da) |
| WO (1) | WO1993020102A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739109A (en) * | 1988-12-16 | 1998-04-14 | Advanced Immunit Inc. | Method of treating neuroinflammatory degenerative diseases |
| EP0729360B1 (en) * | 1993-09-24 | 2004-05-26 | Advanced Immuni T, Inc. | Linear and cyclic peptides for treatment or prevention of crohn's disease and/or ulcerative colitis |
| EP0871466B1 (en) * | 1993-09-24 | 2004-05-06 | Advanced Immuni T, Inc. | Linear and cyclic peptides for the treatment or prevention of eczema/dermatitis |
| AU3080001A (en) * | 1999-11-09 | 2001-06-06 | Advanced Immunit, Inc. | A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t |
| JP4611233B2 (ja) * | 2005-04-06 | 2011-01-12 | ニッタ株式会社 | 歩行訓練支援装置 |
| US20140322250A1 (en) * | 2013-04-26 | 2014-10-30 | Michael Ruff | Peptides for the Treatment of Multiple Sclerosis and Related Diseases |
| EP2832373B1 (en) * | 2013-08-02 | 2017-04-12 | Experimentelle Pharmakologie & Onkologie Berlin Buch | Liposome for blocking site-specifically chemokine-related inflammatory processes in vascular diseases and metastasis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987007614A1 (en) * | 1986-06-03 | 1987-12-17 | Pert Candace B | Small peptides which inhibit binding to t-4 receptors |
| NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
| WO1988009338A1 (en) * | 1987-05-22 | 1988-12-01 | Syntbiotech, Inc. | Synthetic peptides and a method of treating aids |
| US5189022A (en) * | 1988-05-27 | 1993-02-23 | The United States Of America As Represented By The Secretary Of Health And Human Services | Composition for the treatment of chronic fatigue syndrome |
| EP0415999B1 (en) * | 1988-05-27 | 1998-07-22 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Compositions having use as treatment of psoriasis and neuropsychiatric deficits |
-
1993
- 1993-03-29 AT AT99101349T patent/ATE267838T1/de not_active IP Right Cessation
- 1993-03-29 DK DK99101349T patent/DK0960886T3/da active
- 1993-03-29 EP EP99101349A patent/EP0960886B1/en not_active Expired - Lifetime
- 1993-03-29 DK DK93907942T patent/DK0635027T3/da active
- 1993-03-29 UA UA94095852A patent/UA41881C2/uk unknown
- 1993-03-29 ES ES99101349T patent/ES2222625T3/es not_active Expired - Lifetime
- 1993-03-29 WO PCT/GB1993/000649 patent/WO1993020102A1/en not_active Ceased
- 1993-03-29 CA CA002132516A patent/CA2132516A1/en not_active Abandoned
- 1993-03-29 AT AT93907942T patent/ATE194495T1/de not_active IP Right Cessation
- 1993-03-29 AU AU38953/93A patent/AU684713B2/en not_active Ceased
- 1993-03-29 EP EP93907942A patent/EP0635027B1/en not_active Expired - Lifetime
- 1993-03-29 DE DE69333537T patent/DE69333537T2/de not_active Expired - Fee Related
- 1993-03-29 PT PT99101349T patent/PT960886E/pt unknown
- 1993-03-29 DE DE69329023T patent/DE69329023T2/de not_active Expired - Fee Related
- 1993-03-29 ES ES93907942T patent/ES2149203T3/es not_active Expired - Lifetime
- 1993-03-29 JP JP51722093A patent/JP3520084B2/ja not_active Expired - Fee Related
-
1994
- 1994-09-17 KR KR1019940703264A patent/KR100312300B1/ko not_active Expired - Fee Related
-
1998
- 1998-04-22 AU AU63542/98A patent/AU725680B2/en not_active Ceased
-
1999
- 1999-03-31 AU AU22549/99A patent/AU718442B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0635027B1 (en) | 2000-07-12 |
| AU718442B2 (en) | 2000-04-13 |
| DE69329023T2 (de) | 2001-03-22 |
| PT960886E (pt) | 2004-10-29 |
| EP0960886A1 (en) | 1999-12-01 |
| DE69329023D1 (de) | 2000-08-17 |
| CA2132516A1 (en) | 1993-10-14 |
| DE69333537D1 (de) | 2004-07-01 |
| EP0960886B1 (en) | 2004-05-26 |
| ATE267838T1 (de) | 2004-06-15 |
| AU2254999A (en) | 1999-05-20 |
| ATE194495T1 (de) | 2000-07-15 |
| AU6354298A (en) | 1998-06-18 |
| DK0635027T3 (da) | 2000-10-02 |
| EP0635027A1 (en) | 1995-01-25 |
| JP3520084B2 (ja) | 2004-04-19 |
| AU725680B2 (en) | 2000-10-19 |
| DE69333537T2 (de) | 2005-06-16 |
| AU3895393A (en) | 1993-11-08 |
| UA41881C2 (uk) | 2001-10-15 |
| ES2149203T3 (es) | 2000-11-01 |
| KR950700931A (ko) | 1995-02-20 |
| KR100312300B1 (ko) | 2002-03-20 |
| ES2222625T3 (es) | 2005-02-01 |
| JPH07507061A (ja) | 1995-08-03 |
| AU684713B2 (en) | 1998-01-08 |
| WO1993020102A1 (en) | 1993-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9100799L (sv) | Rekombinant derivat av human faktor viii | |
| DE59007517D1 (de) | Neue proteine mit tnf-hemmender wirkung und ihre herstellung. | |
| ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| ATE238345T1 (de) | Protegrine | |
| DK0711305T3 (da) | Protegriner | |
| ATE171712T1 (de) | Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten | |
| ATE118349T1 (de) | Als therapeutika geeignete peptide. | |
| DK0960886T3 (da) | Peptid T og beslægtede peptider til behandling af inflammation, herunder multipel sklerose | |
| BR9306272A (pt) | Peptídeo e composiçao farmacêutica | |
| RU94027578A (ru) | Фармацевтическая композиция и способ лечения рассеянного склероза | |
| WO2001027136A3 (fr) | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire | |
| ATE221084T1 (de) | Neuer megakaryocyten-verstärker | |
| ATE3773T1 (de) | An peptide polymerisationsprodukte gebundene muramyl-peptide und sie enthaltende pharmazeutische zusammensetzungen. | |
| RU94046096A (ru) | Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов | |
| IL102615A (en) | Immunoassy kit for simultaneously detecting antibodies to hiv-1, hiv-2, htlv-1 and htlv-ii and methods for te detections of antibodies | |
| ATE124955T1 (de) | Substrat-peptide. | |
| ATE425988T1 (de) | Peptide mit affinitat fur ein phospholipid und deren verwendung | |
| ES2051152B1 (es) | Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados. | |
| RU94036770A (ru) | Домен ингибитора протеазы, днк, вектор, клетка, способ получения домена, фармацевтическая композиция, применение домена |